Loading the company…
Loading the company…
Families: Pacemaker, ICD & CRT implantation, Coronary intervention (PCI), Peripheral arterial intervention, Spinal cord & DRG stimulation, LAA occlusion & loop recorders.
All companies · Product and company coverage
In the last ten years FDA made 645 decisions for Biotronik (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 5 procedure families, the most in 2026 (86). The latest was on 2026-10-16.
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-10-16 | PMA | P950037-S289 | BIOexpress · Change Design/Components/Specifications/Material |
| 2026-10-16 | PMA | P050023-S209 | BIOexpress · Change Design/Components/Specifications/Material |
| 2026-10-16 | PMA | P000009-S128 | BIOexpress · Change Design/Components/Specifications/Material |
| 2026-10-16 | PMA | P070008-S177 | BIOexpress · Change Design/Components/Specifications/Material |
| 2026-10-13 |
In 2025, Biotronik reported engagement with 5,647 surgeons and other clinicians in the states MedaRep covers, worth $1.9M in consulting, speaking, meals and travel for its device products, the most in California ($332K to 716). Royalties are left out.
| PMA |
| P950037-S298 |
| Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Enticos 4 DR, Enticos · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Biotronik.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: California ($332K, 716 engaged), Florida ($265K, 526 engaged), New York ($144K, 475 engaged), Texas ($135K, 577 engaged), Georgia ($127K, 243 engaged).